James Grogan1, Karen Roos2. 1. Indiana University, School of Medicine, 340 W 10th St #6200, Indianapolis, IN, 46202, USA. groganj@umail.iu.edu. 2. Indiana University, School of Medicine, 340 W 10th St #6200, Indianapolis, IN, 46202, USA.
Abstract
PURPOSE OF REVIEW: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). RECENT FINDINGS: Serogroup B meningitis represents 30% of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY).
PURPOSE OF REVIEW: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). RECENT FINDINGS: Serogroup B meningitis represents 30% of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY).
Entities:
Keywords:
Bexsero; Meningococcal vaccine; Neisseria meningitidis; Princeton University meningitis outbreak; Serogroup B meningococcus; Trumenba
Authors: Lucy A McNamara; Alice M Shumate; Peter Johnsen; Jessica R MacNeil; Manisha Patel; Tina Bhavsar; Amanda C Cohn; Jill Dinitz-Sklar; Jonathan Duffy; Janet Finnie; Denise Garon; Robert Hary; Fang Hu; Hajime Kamiya; Hye-Joo Kim; John Kolligian; Janet Neglia; Judith Oakley; Jacqueline Wagner; Kathy Wagner; Xin Wang; Yon Yu; Barbara Montana; Christina Tan; Robin Izzo; Thomas A Clark Journal: Pediatrics Date: 2015-05 Impact factor: 7.124
Authors: Amanda C Cohn; Jessica R MacNeil; Lee H Harrison; Cynthia Hatcher; Jordan Theodore; Mark Schmidt; Tracy Pondo; Kathryn E Arnold; Joan Baumbach; Nancy Bennett; Allen S Craig; Monica Farley; Ken Gershman; Susan Petit; Ruth Lynfield; Arthur Reingold; William Schaffner; Kathleen A Shutt; Elizabeth R Zell; Leonard W Mayer; Thomas Clark; David Stephens; Nancy E Messonnier Journal: Clin Infect Dis Date: 2010-01-15 Impact factor: 9.079
Authors: Rodolfo Villena; Marco Aurelio P Safadi; María Teresa Valenzuela; Juan P Torres; Adam Finn; Miguel O'Ryan Journal: Hum Vaccin Immunother Date: 2018-04-30 Impact factor: 3.452